HC Wainwright restated their buy rating on shares of Annovis Bio (NYSE:ANVS - Free Report) in a research report released on Monday,Benzinga reports. HC Wainwright currently has a $30.00 price target on the stock.
Several other equities research analysts have also recently commented on the company. Maxim Group raised Annovis Bio from a "hold" rating to a "buy" rating and set a $25.00 target price for the company in a research note on Friday, October 25th. EF Hutton Acquisition Co. I upgraded shares of Annovis Bio to a "strong-buy" rating in a research note on Tuesday, August 13th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $32.17.
View Our Latest Stock Analysis on Annovis Bio
Annovis Bio Trading Down 7.4 %
Shares of ANVS stock traded down $0.60 during mid-day trading on Monday, reaching $7.56. The stock had a trading volume of 574,777 shares, compared to its average volume of 774,129. The company has a market cap of $98.69 million, a P/E ratio of -1.83 and a beta of 1.70. The business has a 50-day simple moving average of $8.53 and a 200 day simple moving average of $8.39. Annovis Bio has a 12-month low of $4.53 and a 12-month high of $22.49.
Annovis Bio (NYSE:ANVS - Get Free Report) last announced its earnings results on Thursday, August 15th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.19. Research analysts anticipate that Annovis Bio will post -2.53 EPS for the current year.
Hedge Funds Weigh In On Annovis Bio
Several large investors have recently bought and sold shares of the stock. Cetera Advisors LLC bought a new stake in shares of Annovis Bio during the first quarter valued at approximately $122,000. Greenwich Wealth Management LLC boosted its stake in shares of Annovis Bio by 19.9% in the second quarter. Greenwich Wealth Management LLC now owns 15,075 shares of the company's stock worth $87,000 after acquiring an additional 2,500 shares during the period. XTX Topco Ltd bought a new stake in shares of Annovis Bio in the second quarter worth about $115,000. Quest Partners LLC purchased a new stake in Annovis Bio during the third quarter valued at approximately $371,000. Finally, Vanguard Group Inc. lifted its position in shares of Annovis Bio by 6.1% during the first quarter. Vanguard Group Inc. now owns 357,942 shares of the company's stock worth $4,260,000 after purchasing an additional 20,588 shares during the last quarter. 15.83% of the stock is currently owned by institutional investors.
Annovis Bio Company Profile
(
Get Free Report)
Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.
Featured Stories
Before you consider Annovis Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annovis Bio wasn't on the list.
While Annovis Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
